# Ashish M. Kamat

Source: https://onco.cc/people/ashish-kamat/  
OnCo record `ashish-kamat` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Urologist who set the definitions for BCG-unresponsive bladder cancer and leads the International Bladder Cancer Group.

## Summary

Ashish Kamat led the consensus that defined BCG-unresponsive non-muscle-invasive bladder cancer and the trial endpoints now used by regulators, and has led studies of BCG dosing, intravesical therapy and urinary biomarkers. He is president of the International Bladder Cancer Group and a senior author of the Lancet seminar on bladder cancer. His work shapes the entire non-muscle-invasive trial landscape.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: urothelial; surgery; bcg
- Role: Professor of Urology and Cancer Biology, MD Anderson Cancer Center
- Specialisms: Non-muscle-invasive bladder cancer; BCG immunotherapy; Urologic oncology; Trial design standards

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Kamat%20AM%5BAuthor%5D%20bladder%20BCG

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)

---
JSON: https://onco.cc/api/v1/entities/ashish-kamat.json